SAB BIOTHERAPEUTICS INC Financials
SAB BIOTHERAPEUTICS INC (SABS) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
SAB's dominant mechanic is a development-stage cash model: research spending exceeds sales, and financing—not operations—supports expansion.
FY2025 net income of$13.3M coexisted with an operating loss of-$49.0M . Operating cash flow of-$44.8M confirms the positive bottom line was not produced by the operating engine, separating reported profit from underlying cash economics.
In FY2024, R&D spending was
FY2025 financing cash flow of
Financial Health Signals
SAB BIOTHERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
SAB BIOTHERAPEUTICS INC scores 8.86, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($357.6M) relative to total liabilities ($21.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
SAB BIOTHERAPEUTICS INC passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, SAB BIOTHERAPEUTICS INC used $3.37 of operating cash (-$44.8M OCF vs $13.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
SAB BIOTHERAPEUTICS INC reported an operating loss of $49.0M against $241K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
SAB BIOTHERAPEUTICS INC generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
SAB BIOTHERAPEUTICS INC's EBITDA was -$46.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.3% from the prior year.
SAB BIOTHERAPEUTICS INC reported $13.3M in net income in fiscal year 2025. This represents an increase of 138.9% from the prior year.
SAB BIOTHERAPEUTICS INC earned -$0.79 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
SAB BIOTHERAPEUTICS INC recorded an outflow of $45.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 32.0% from the prior year.
SAB BIOTHERAPEUTICS INC held $10.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
SAB BIOTHERAPEUTICS INC's ROE was 8.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 140.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
SAB BIOTHERAPEUTICS INC invested $34.4M in research and development in fiscal year 2025. This represents an increase of 13.6% from the prior year.
SAB BIOTHERAPEUTICS INC invested $933K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 176.7% from the prior year.
Not reported for fiscal year 2025.
SABS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $16.2M+20.7% | $13.4M | N/A | $9.0M+28.2% | $7.0M-8.6% | $7.7M | N/A | $7.8M |
| SG&A Expenses | $7.2M+9.2% | $6.6M | N/A | $3.7M+35.6% | $2.7M-12.2% | $3.1M | N/A | $3.5M |
| Operating Income | -$23.4M-16.9% | -$20.0M | N/A | -$12.7M-30.3% | -$9.7M+9.7% | -$10.8M | N/A | -$11.3M |
| Interest Expense | $62K-1.2% | $63K | N/A | $43K-32.4% | $64K-8.0% | $70K | N/A | $78K |
| Net Income | -$22.5M-19.2% | -$18.9M | N/A | $45.4M+549.3% | -$10.1M-94.6% | -$5.2M | N/A | -$10.3M |
| EPS (Diluted) | -$0.28+20.0% | -$0.35+23.9% | -$0.46-119.0% | -$0.21 | -$1.09-94.6% | -$0.56+54.5% | -$1.23-9.8% | -$1.12 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
SABS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $238.2M-4.1% | $248.5M+43.8% | $172.8M-5.8% | $183.4M+508.9% | $30.1M-21.0% | $38.1M-13.7% | $44.2M-17.8% | $53.8M |
| Current Assets | $107.9M-4.3% | $112.8M+11.6% | $101.1M-10.8% | $113.3M+1117.0% | $9.3M-42.9% | $16.3M-31.5% | $23.8M-26.9% | $32.5M |
| Cash & Equivalents | $8.3M-59.7% | $20.5M+95.4% | $10.5M-64.3% | $29.4M+696.9% | $3.7M-34.5% | $5.6M-36.6% | $8.9M-3.0% | $9.2M |
| Total Liabilities | $23.4M+10.4% | $21.2M-0.4% | $21.3M+16.0% | $18.4M+1.4% | $18.1M+8.4% | $16.7M-8.3% | $18.2M+7.9% | $16.9M |
| Current Liabilities | $11.7M+18.8% | $9.9M-7.8% | $10.7M-1.0% | $10.8M+1.1% | $10.7M+10.6% | $9.7M+21.0% | $8.0M-9.5% | $8.8M |
| Total Equity | $214.8M-5.5% | $227.2M+50.0% | $151.5M-8.2% | $165.1M+1273.8% | $12.0M-43.9% | $21.4M-17.6% | $26.0M-29.6% | $36.9M |
| Retained Earnings | -$152.3M-17.3% | -$129.8M-17.0% | -$110.9M-17.9% | -$94.0M+32.6% | -$139.5M-7.8% | -$129.4M-4.2% | -$124.2M-10.1% | -$112.8M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SABS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.8M+31.0% | -$14.3M+14.9% | -$16.8M-28.6% | -$13.0M-82.4% | -$7.2M+8.3% | -$7.8M+18.2% | -$9.5M-51.5% | -$6.3M |
| Capital Expenditures | $1.6M+61.3% | $983K | N/A | N/A | N/A | N/A | $55K-44.8% | $100K |
| Free Cash Flow | -$11.4M+25.1% | -$15.3M | N/A | N/A | N/A | N/A | -$9.6M-50.0% | -$6.4M |
| Investing Cash Flow | -$4.9M+92.6% | -$65.6M-3747.7% | -$1.7M+98.7% | -$129.9M-2598.5% | $5.2M+11.3% | $4.7M-49.9% | $9.3M+909.5% | -$1.2M |
| Financing Cash Flow | $2.4M-97.4% | $89.9M+215815.8% | -$42K-100.0% | $168.7M+97039.4% | -$174K0.0% | -$174K-180.2% | $217K+132.2% | -$674K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SABS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -10.5%-2.2pp | -8.3% | N/A | 27.5%+111.7pp | -84.2%-59.9pp | -24.3% | N/A | -28.1% |
| Return on Assets | -9.4%-1.9pp | -7.6% | N/A | 24.8%+58.3pp | -33.6%-19.9pp | -13.6% | N/A | -19.2% |
| Current Ratio | 9.22-2.2x | 11.45+2.0x | 9.46-1.0x | 10.50+9.6x | 0.87-0.8x | 1.69-1.3x | 2.98-0.7x | 3.69 |
| Debt-to-Equity | 0.110.0x | 0.090.0x | 0.140.0x | 0.11-1.4x | 1.51+0.7x | 0.78+0.1x | 0.70+0.2x | 0.46 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where SAB BIOTHERAPEUTICS INC Ranks
Frequently Asked Questions
What is SAB BIOTHERAPEUTICS INC's annual revenue?
SAB BIOTHERAPEUTICS INC (SABS) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is SAB BIOTHERAPEUTICS INC's revenue growing?
SAB BIOTHERAPEUTICS INC (SABS) revenue declined by 100.0% year-over-year, from $1.3M to $0 in fiscal year 2025.
Is SAB BIOTHERAPEUTICS INC profitable?
Yes, SAB BIOTHERAPEUTICS INC (SABS) reported a net income of $13.3M in fiscal year 2025.
What is SAB BIOTHERAPEUTICS INC's EBITDA?
SAB BIOTHERAPEUTICS INC (SABS) had EBITDA of -$46.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is SAB BIOTHERAPEUTICS INC's return on equity (ROE)?
SAB BIOTHERAPEUTICS INC (SABS) has a return on equity of 8.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is SAB BIOTHERAPEUTICS INC's free cash flow?
SAB BIOTHERAPEUTICS INC (SABS) recorded an outflow of $45.7M in free cash flow during fiscal year 2025. This represents a -32.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is SAB BIOTHERAPEUTICS INC's operating cash flow?
SAB BIOTHERAPEUTICS INC (SABS) recorded an outflow of $44.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are SAB BIOTHERAPEUTICS INC's total assets?
SAB BIOTHERAPEUTICS INC (SABS) had $172.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are SAB BIOTHERAPEUTICS INC's capital expenditures?
SAB BIOTHERAPEUTICS INC (SABS) invested $933K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does SAB BIOTHERAPEUTICS INC spend on research and development?
SAB BIOTHERAPEUTICS INC (SABS) invested $34.4M in research and development during fiscal year 2025.
What is SAB BIOTHERAPEUTICS INC's current ratio?
SAB BIOTHERAPEUTICS INC (SABS) had a current ratio of 9.46 as of fiscal year 2025, which is generally considered healthy.
What is SAB BIOTHERAPEUTICS INC's debt-to-equity ratio?
SAB BIOTHERAPEUTICS INC (SABS) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is SAB BIOTHERAPEUTICS INC's return on assets (ROA)?
SAB BIOTHERAPEUTICS INC (SABS) had a return on assets of 7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does SAB BIOTHERAPEUTICS INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, SAB BIOTHERAPEUTICS INC (SABS) held $143.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $44.8M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is SAB BIOTHERAPEUTICS INC's Altman Z-Score?
SAB BIOTHERAPEUTICS INC (SABS) has an Altman Z-Score of 8.86, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is SAB BIOTHERAPEUTICS INC's Piotroski F-Score?
SAB BIOTHERAPEUTICS INC (SABS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are SAB BIOTHERAPEUTICS INC's earnings high quality?
For every $1 of reported earnings, SAB BIOTHERAPEUTICS INC (SABS) used $3.37 of operating cash (-$44.8M OCF vs $13.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can SAB BIOTHERAPEUTICS INC cover its interest payments?
SAB BIOTHERAPEUTICS INC (SABS) reported an operating loss of $49.0M against $241K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.